SOLENO THERAPEUTICS INC 8-K

What Happened
Soleno Therapeutics, Inc. (SLNO) announced on April 5, 2026 that it entered into an Agreement and Plan of Merger with Neurocrine Biosciences, Inc. and a Neurocrine subsidiary. Neurocrine will commence a cash tender offer to buy all outstanding Soleno shares at $53.00 per share, and if successful the offer will be followed by a merger making Soleno a wholly owned subsidiary of Neurocrine. The Soleno board recommends that stockholders accept the Offer. A joint press release was issued April 6, 2026.

Key Details

• Offer price: $53.00 per share in cash (no interest), subject to withholding taxes.
• Timing: Neurocrine must commence the Offer within 10 business days of the April 5, 2026 agreement and keep it open for at least 20 business days (subject to extension). Outside termination date: October 5, 2026 (subject to certain extensions).
• Minimum acceptance condition: Purchaser will accept payment only if shares validly tendered (plus shares beneficially owned by Neurocrine and its subsidiaries) equal more than 50% of outstanding shares at Offer expiration.
• Conditions & approvals: customary closing conditions, including accuracy of certain company reps/warranties, covenants performance, absence of a material adverse effect, and expiration/termination of the Hart-Scott-Rodino antitrust waiting period. The Offer is not conditioned on financing.
• Stock‑based awards: in‑the‑money company options will vest and be cashed out for their intrinsic value; out‑of‑the‑money options will be canceled with no payment; outstanding warrants will be treated as cashless exercised at closing (or subject to agreed termination arrangements).
• Support: Two principal stockholders (Anish Bhatnagar and James Mackaness), holding ~1.01% combined, signed tender and support agreements to tender and vote their shares in favor of the transaction.
• Break fees: Soleno would owe Neurocrine $95.25 million if Soleno terminates to accept a superior proposal under specified circumstances; Neurocrine would owe Soleno $141.5 million if antitrust action prevents the Offer under certain conditions.

Why It Matters
This is a definitive acquisition agreement that sets a firm cash price of $53.00 per share and a clear path (tender offer then merger) for Neurocrine to take Soleno private. The board’s recommendation and the absence of a financing condition reduce some execution risk for shareholders, but closing still depends on tender levels, customary contractual conditions and antitrust clearance. Treatment of options and warrants affects employees and option holders—some awards will be cashed out while out‑of‑the‑money options may be canceled. Retail investors should review the full Merger Agreement and the forthcoming offer materials for timing, how to tender shares, and any appraisal rights.